Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199600 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marina Z Jovanović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Mammary Neoplasms, Experimental, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Immunological, Interleukin-1 Receptor-Like 1 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia under Grant Agreements with University of Kragujevac-Faculty of Medical Scien…, Medical faculty of Military Medical Academy, Ministry of Science, Technological Development and Innovation.
Abstract (Originalsprache)
Despite advances in immunotherapy, the treatment of breast cancer still remains a major global problem. In a previous study, we showed that co-blockade of Interleukin-33/ST2 and Programmed death-1/Programmed death-ligand (PD-1/PD-L) signaling pathways strongly slows progression by enhancing the antitumor capacity of natural killer (NK) cells. The main aim of this study is to elucidate the exact effect of co-blockade on the T lymphocyte and macrophage effector cells. 4T1 cells were used to induct breast cancer in female BALB/C and BALB/C ST2−/− mice. The mice, both BALB/C and BALB/C ST2−/−, were treated with anti-PD-1 antibody on certain days. After the mice were sacrificed, T cells and macrophages were analyzed using flow cytometry; dual co-blockade increased significantly the percentage of M1 macrophages in the tumor microenvironment, followed by an increase in expression of CD86+ and TNFα+. T cell accumulation was significantly higher in the spleen and within the tumor microenvironment, with elevation in activation markers such as Interleukin-17, CD69, NKG2D, and FasL and a decrease in Interleukin-10 and FoxP3 expression. Co-blockade of the PD-1/PD-L axes and IL-33/ST2 axes shows promising results in reestablishing an effective immune response and offers a new perspective on improving immune response to breast carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Department of Otorhinolaryngology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Department of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia.
- Medical Faculty of the Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
- Institute for Transfusiology and Haemobiology, Military Medical Academy, 11000 Belgrade, Serbia.
ORCID-Profile: Miodrag Jocić, Marina M Jovanović, Ivan Jovanović
Förderung
- Ministry of Science, Technological Development and Innovation, Republic of Serbia under Grant Agreements with University of Kragujevac-Faculty of Medical Scien…
- Medical faculty of Military Medical Academy
- Ministry of Science, Technological Development and Innovation
Zitieren
APA
Jovanović, M. Z., Jurišević, M., Jovanović, M., Gajović, N., Jocić, M., Jovanović, M. M., Milev, B., Vasiljev, K. D., & Jovanović, I. (2025). Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199600
Vancouver
Jovanović MZ, Jurišević M, Jovanović M, Gajović N, Jocić M, Jovanović MM, et al. Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199600
BibTeX
@article{Jovanovi2025,
author = {Jovanović, Marina Z and Jurišević, Milena and Jovanović, Milan and Gajović, Nevena and Jocić, Miodrag and Jovanović, Marina M and Milev, Boško and Vasiljev, Krstina Doklestić and Jovanović, Ivan},
title = {Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199600}
}
EUVIMED